<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879837</url>
  </required_header>
  <id_info>
    <org_study_id>TPI-18-03</org_study_id>
    <nct_id>NCT03879837</nct_id>
  </id_info>
  <brief_title>Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg</brief_title>
  <official_title>A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study&#xD;
      to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose&#xD;
      Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Actual">July 9, 2021</completion_date>
  <primary_completion_date type="Actual">May 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in baseline adjusted morning pre-dose FEV1 from the time of treatment randomization to Week 4.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Superiority over Placebo</measure>
    <time_frame>Approximately 4 Weeks</time_frame>
    <description>To confirm the Test and Reference listed Drug products are statistically superior to placebo (p&lt; 0.05) on the primary study endpoint.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1902</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Investigational Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Listed Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pressurized metered dose inhaler, no active content</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate pressurized metered dose inhaler</intervention_name>
    <description>110 mcg per actuation</description>
    <arm_group_label>Investigational Test Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flovent HFA pressurized metered dose inhaler</intervention_name>
    <description>110 mcg per actuation</description>
    <arm_group_label>Reference Listed Drug</arm_group_label>
    <other_name>Fluticasone propionate pressurized metered dose inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pressurized metered dose inhaler</intervention_name>
    <description>no active content</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult ≥18 and ≤75 years of age male or female subjects of non-child bearing potential&#xD;
             or of child bearing potential committing to consistent and correct use of an&#xD;
             acceptable method of birth control.&#xD;
&#xD;
          2. Body mass index (BMI) ≥18 and ≤45.&#xD;
&#xD;
          3. Diagnosis of asthma, as defined by the NAEPP-EPR3 at least 12 months prior to&#xD;
             Enrollment at Screening Visit 1a.&#xD;
&#xD;
          4. Pre bronchodilator highest forced expiratory volume in 1 second (FEV1) ≥45% and ≤85%&#xD;
             of predicted normal value at Screening Visit 1b and on the first day of treatment&#xD;
             prior to randomization.&#xD;
&#xD;
          5. Reversibility of airway obstruction ≥15% of FEV1 within 30 minutes of 360mcg albuterol&#xD;
             inhalation (4 puffs).&#xD;
&#xD;
          6. Subjects should be stable on their chronic asthma treatment regimen for at least 4&#xD;
             weeks prior to Enrollment at Screening Visit 1a.&#xD;
&#xD;
          7. Currently non-smoking, defined as abstinence from all smoking, including marijuana and&#xD;
             all tobacco products (i.e., e-cigarettes, cigarettes, cigars, pipe, ortobacco) within&#xD;
             the past year, a negative cotinine screening test at Screening Visit 1b, and &lt;10 pack&#xD;
             years of historical use.&#xD;
&#xD;
          8. Able to replace current short-acting β agonist (SABA) with study issued albuterol&#xD;
             inhaler for use as needed for the duration of the study.&#xD;
&#xD;
          9. Able to withhold all inhaled SABAs for at least 6 hours prior to lung function&#xD;
             assessments on study visits.&#xD;
&#xD;
         10. Able to withhold all inhaled long acting β agonists (LABA) 24 hours before Screening&#xD;
             Visit 1b.&#xD;
&#xD;
         11. Able to discontinue current asthma medications (e.g., inhaled corticosteroids[ICS],&#xD;
             LABA, etc.) during the Run-in period and for remainder of the study.&#xD;
&#xD;
         12. Able to comply with study procedures, including correct use of inhaler devices and&#xD;
             home peak expiratory flow (PEF) device, and maintaining an electronic diary (eDiary).&#xD;
&#xD;
         13. Willingness to give their written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life-threatening asthma, defined as a history of asthma episodes(s) requiring&#xD;
             intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic&#xD;
             seizures, asthma related syncopal episode(s), or hospitalizations due to asthma within&#xD;
             the past year prior to Enrollment, or during the Screening or Run-in period.&#xD;
&#xD;
          2. History of significant respiratory disease other than asthma (e.g., chronic&#xD;
             obstructive pulmonary disease [COPD], interstitial lung disease, chronic bronchitis,&#xD;
             emphysema, etc.).&#xD;
&#xD;
          3. Evidence or history of clinically significant disease or abnormality including&#xD;
             congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery&#xD;
             disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or&#xD;
             current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal,&#xD;
             cardiovascular, endocrine, or other diseases that, in the opinion of the Investigator,&#xD;
             would put the subject at risk through study participation, or would affect the study&#xD;
             analyses if the disease exacerbates during the study.&#xD;
&#xD;
          4. Viral or bacterial, upper/lower respiratory tract infection (U/LRTI), or sinus, or&#xD;
             middle ear infection within 4 weeks prior to Screening Visit 1b, during the Run-in&#xD;
             period, or on the first day of treatment prior to randomization.&#xD;
&#xD;
          5. Hypersensitivity to any sympathomimetic drug (e.g., albuterol) or any inhaled,&#xD;
             intranasal, or systemic corticosteroid therapy.&#xD;
&#xD;
          6. Hypersensitivity to any of the ingredients of FP pMDI or Flovent HFA.&#xD;
&#xD;
          7. Subjects receiving β2 blockers, anti-arrhythmics, anti-depressants, and/or monoamine&#xD;
             oxidase inhibitors within 4 weeks prior to Screening Visit 1b.&#xD;
&#xD;
          8. Subjects who required systemic or oral corticosteroids (for any reason) within the&#xD;
             past 6 months prior to Screening Visit 1b.&#xD;
&#xD;
          9. Subjects receiving medications that are strong cytochrome P4503A4 inhibitors (e.g.,&#xD;
             ritonavir, ketoconazole, itraconazole) within 2 weeks prior to Screening Visit 1b.&#xD;
&#xD;
         10. Subjects receiving any approved or investigational biological treatment for asthma&#xD;
             (e.g., omalizumab, mepolizumab) within 6 months prior to Screening Visit 1b.&#xD;
&#xD;
         11. Subjects with clinically relevant abnormal chemistry laboratory findings at Screening&#xD;
             Visit 1b as assessed by the Investigator.&#xD;
&#xD;
         12. Subjects with clinically significant electrocardiogram (ECG) findings at Screening&#xD;
             Visit 1b as assessed by the Investigator and/or cardiologist.&#xD;
&#xD;
         13. Subjects who have received any Investigational Product (IP) within 1 month prior to&#xD;
             Screening Visit 1b and as described in the Washout Table in Appendix 1.&#xD;
&#xD;
         14. Female subjects who are pregnant or breast feeding.&#xD;
&#xD;
         15. Evidence of oral candidiasis at Screening or randomization, or history within 1year&#xD;
             prior to Screening Visit 1b.&#xD;
&#xD;
         16. Evidence or history of tuberculosis, hypercorticism, or adrenal suppression.&#xD;
&#xD;
         17. Evidence or history within the 6 months prior to Screening Visit 1b of clinically&#xD;
             relevant eye problems such as cataracts. Any previous diagnosis or treatment for&#xD;
             ocular hypertension or glaucoma is exclusionary.&#xD;
&#xD;
         18. Subjects with hyperbilirubinemia (defined as aspartate aminotransferase [AST] or&#xD;
             alanine aminotransferase [ALT] ≥3 times the upper limit of the normal range [ULN], or&#xD;
             bilirubin ≥2 times the ULN) or Hy's Law events.&#xD;
&#xD;
         19. Evidence or history of drug or alcohol abuse in the 2 years prior to Enrollment at&#xD;
             Screening Visit 1a or a positive drug or alcohol test at Screening Visit 1b.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participant data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

